High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
Standard
High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. / Al-Kuraya, Khawla; Siraj, Abdul K; Bavi, Prashant; Al-Jommah, Naif; Ezzat, Adnan; Sheikh, Salwa; Amr, Samir; Al-Dayel, Fouad; Simon, Ronald; Guido, Sauter.
In: HUM PATHOL, Vol. 37, No. 4, 4, 2006, p. 453-457.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
AU - Al-Kuraya, Khawla
AU - Siraj, Abdul K
AU - Bavi, Prashant
AU - Al-Jommah, Naif
AU - Ezzat, Adnan
AU - Sheikh, Salwa
AU - Amr, Samir
AU - Al-Dayel, Fouad
AU - Simon, Ronald
AU - Guido, Sauter
PY - 2006
Y1 - 2006
N2 - Epidermal growth factor receptor (EGFR) exon 18-21 mutations were shown to be highly predictive of response to gefitinib (Iressa) therapy in lung cancer. Studies on Western and Japanese lung cancers have indicated substantial differences in the EGFR mutation frequency between these populations. To investigate the prevalence of EGFR in another distinct ethnic group, EGFR alterations were studied in 47 consecutive non small cell lung cancers from Saudi Arabia by immunohistochemistry, fluorescence in situ hybridization, and DNA sequencing. Detectable EGFR expression was seen in 69.8% of 43 interpretable cancers. Epidermal growth factor receptor amplification, present in 15.3% of 39 analyzable cancers, was strongly associated with high levels of EGFR expression (P = .0047). Only 1 exon 18-21 mutation was seen among 34 lung cancers that could be successfully sequenced. It is concluded that EGFR exon 18-21 mutations are rare in Middle East patients with lung cancer and occur in a similar range as in Western patients. The remarkable high rate of EGFR gene amplifications could potentially facilitate studies on the predictive role of gene copy number changes for response to anti-EGFR therapies in Middle East patient sets.
AB - Epidermal growth factor receptor (EGFR) exon 18-21 mutations were shown to be highly predictive of response to gefitinib (Iressa) therapy in lung cancer. Studies on Western and Japanese lung cancers have indicated substantial differences in the EGFR mutation frequency between these populations. To investigate the prevalence of EGFR in another distinct ethnic group, EGFR alterations were studied in 47 consecutive non small cell lung cancers from Saudi Arabia by immunohistochemistry, fluorescence in situ hybridization, and DNA sequencing. Detectable EGFR expression was seen in 69.8% of 43 interpretable cancers. Epidermal growth factor receptor amplification, present in 15.3% of 39 analyzable cancers, was strongly associated with high levels of EGFR expression (P = .0047). Only 1 exon 18-21 mutation was seen among 34 lung cancers that could be successfully sequenced. It is concluded that EGFR exon 18-21 mutations are rare in Middle East patients with lung cancer and occur in a similar range as in Western patients. The remarkable high rate of EGFR gene amplifications could potentially facilitate studies on the predictive role of gene copy number changes for response to anti-EGFR therapies in Middle East patient sets.
M3 - SCORING: Zeitschriftenaufsatz
VL - 37
SP - 453
EP - 457
JO - HUM PATHOL
JF - HUM PATHOL
SN - 0046-8177
IS - 4
M1 - 4
ER -
